title: Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
abstract: BACKGROUND
  There is much controversy as to whether or not treatment of Helicobacter pylori reduces the occurrence of peptic ulcers during therapy with a non-steroidal anti-inflammatory drug (NSAID).
  
  
  OBJECTIVE
  To assess the efficacy of triple therapy or omeprazole on the occurrence of diclofenac associated ulcers in H pylori positive patients.
  
  
  METHODS
  This was a randomised, double blind, placebo controlled, multicentre trial in H pylori positive patients requiring NSAID therapy who had no past or current peptic ulcer. They received diclofenac 50 mg twice daily for five weeks in combination with one of the four randomly assigned treatments: anti-H pylori treatment for one week (omeprazole 20 mg+clarithromycin 500 mg+amoxicillin 1 g, all twice daily) followed by placebo for four weeks (OAC-P); anti-H pylori treatment for one week followed by antisecretory treatment with omeprazole 20 mg once daily for four weeks (OAC-O); omeprazole 20 mg once daily for five weeks (O-O); or placebo for five weeks (P-P). Patients were endoscoped before and after treatment.
  
  
  RESULTS
  Data from 660 patients were included in an intention to treat analysis. The occurrence of peptic ulcers in the four treatment groups during the study period was: 1.2% for OAC-P, 1.2% for OAC-O, 0% for O-O, and 5.8% for P-P (p<0.05 between placebo and all active treatment groups). Patients who received active treatment developed therapy requiring dyspeptic symptoms less frequently than those who received placebo (p<0.05 between placebo and all active treatment groups).
  
  
  CONCLUSIONS
  In H pylori infected patients, all three active therapies reduced the occurrence of NSAID associated peptic ulcer and dyspeptic symptoms requiring therapy.
authors.affiliation: Department of Medicine, Jung-Stilling Hospital, Siegen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Labenz
authors.forename: A L
authors.initials: AL
authors.lastname: Blum
authors.forename: W W
authors.initials: WW
authors.lastname: Bolten
authors.forename: B
authors.initials: B
authors.lastname: Dragosics
authors.forename: W
authors.initials: W
authors.lastname: Rösch
authors.forename: M
authors.initials: M
authors.lastname: Stolte
authors.forename: H R
authors.initials: HR
authors.lastname: Koelz
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004008:Diclofenac / Q000009:adverse effects*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004415:Dyspepsia / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D004008:Diclofenac; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole